BioSpace News Archive

Sanofi announced that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Sanofi’s pending acquisition of Provention Bio, Inc.

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023.

Agile Therapeutics, Inc., a women’s healthcare company, announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023.

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) granted marketing authorization of the MISHA™ Knee System, an implantable shock absorber (ISA) for the knee.

Mirum Pharmaceuticals, Inc. announced that on April 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,950 shares of common stock and 12,960 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

SK Biopharmaceuticals, an innovative global pharmaceuticals company, announced that its digital wearable devices – Zero WiredTM and Zero EarbudsTM – have won the Red Dot Design Award 2023 in the healthcare category for outstanding design.

Denali Therapeutics Inc. today announced that new data from the 28-day treatment period of the Phase 1b study of DNL343 in participants with amyotrophic lateral sclerosis (ALS) will be presented at the 75th Annual Meeting of the American Academy of Neurology (AAN), which will be held April 22-27, 2023, in Boston, Massachusetts.

Valitor today announced that data reviewing the therapeutic potential of its Multivalent Polymer (MVP) technology in oncology has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.